A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia

Table 2 Model results

	ICER vs IPC, AUD per QALY gained	CE QALY simulations vs IPC, %	ICER vs IPC, AUD per VTE avoided	CE VTE simulations vs IPC, %
LMWH	Dominated	1.2	Dominated	0.2
Apixaban	12,656	76.4	3022	46.4
Dabigatran	51,224	55.2	73,824	21.4
Rivaroxaban	55,714	30.8	10,947	10
IPC + LMWH (7 days + 23 days)	Dominated	1.8	Dominated	3.2
IPC + apixaban (7 days + 23 days)	14,000	87.8	4960	36.6

Outcomes and costs of the assessed treatment modalities compared to IPC. ICER vs IPC, AUD per QALY gained: incremental costs to gain one additional QALY; CE QALY simulations vs. IPC: percent of simulations where the comparator was considered more cost-effective than IPC regarding quality of life; ICER vs IPC, AUD per VTE avoided: incremental costs to avoid one additional VTE event; CE VTE simulations vs IPC: percentage of simulations where the comparator was considered more cost-effective than IPC regarding VTE prevention
AUD Australian dollars, CE cost-effective, Dominated more expensive and fewer QALYs accumulated compared to IPC alone, ICER incremental cost-effectiveness ratio, IPC intermittent pneumatic compression, LMWH low-molecular-weight heparin, QALY quality-adjusted life year, VTE venous thromboembolism

ISSN: 1749-799X